Tags

Type your tag names separated by a space and hit enter

Antiproliferative effect of genistein and adriamycin against estrogen-dependent and -independent human breast carcinoma cell lines.
Anticancer Res. 1994 May-Jun; 14(3A):1221-6.AR

Abstract

The effects of the combination of genistein, a tyrosine kinase inhibitor, and adriamycin, an anthracycline anticancer drug, were studied in three human breast carcinoma cell lines (MCF-7/WT, MCF-7/ADR(R) and MDA-231) differing in estrogen receptor status and adriamycin sensitivity. Genistein inhibited cell proliferation in all three cell lines (IC50 between 7.0 and 37.0 microM). The combination produced additive to synergistic effects; epidermal growth factor receptor modulation by adriamycin does not seem to be involved in this interaction. The possible therapeutic advantage of this drug combination, especially on hormone-independent and multidrug resistant tumor cells, deserves further investigation.

Authors+Show Affiliations

Institute of Pharmacology, University of Milan, Italy.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8074476

Citation

Monti, E, and B K. Sinha. "Antiproliferative Effect of Genistein and Adriamycin Against Estrogen-dependent and -independent Human Breast Carcinoma Cell Lines." Anticancer Research, vol. 14, no. 3A, 1994, pp. 1221-6.
Monti E, Sinha BK. Antiproliferative effect of genistein and adriamycin against estrogen-dependent and -independent human breast carcinoma cell lines. Anticancer Res. 1994;14(3A):1221-6.
Monti, E., & Sinha, B. K. (1994). Antiproliferative effect of genistein and adriamycin against estrogen-dependent and -independent human breast carcinoma cell lines. Anticancer Research, 14(3A), 1221-6.
Monti E, Sinha BK. Antiproliferative Effect of Genistein and Adriamycin Against Estrogen-dependent and -independent Human Breast Carcinoma Cell Lines. Anticancer Res. 1994 May-Jun;14(3A):1221-6. PubMed PMID: 8074476.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antiproliferative effect of genistein and adriamycin against estrogen-dependent and -independent human breast carcinoma cell lines. AU - Monti,E, AU - Sinha,B K, PY - 1994/5/1/pubmed PY - 1994/5/1/medline PY - 1994/5/1/entrez SP - 1221 EP - 6 JF - Anticancer research JO - Anticancer Res VL - 14 IS - 3A N2 - The effects of the combination of genistein, a tyrosine kinase inhibitor, and adriamycin, an anthracycline anticancer drug, were studied in three human breast carcinoma cell lines (MCF-7/WT, MCF-7/ADR(R) and MDA-231) differing in estrogen receptor status and adriamycin sensitivity. Genistein inhibited cell proliferation in all three cell lines (IC50 between 7.0 and 37.0 microM). The combination produced additive to synergistic effects; epidermal growth factor receptor modulation by adriamycin does not seem to be involved in this interaction. The possible therapeutic advantage of this drug combination, especially on hormone-independent and multidrug resistant tumor cells, deserves further investigation. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/8074476/Antiproliferative_effect_of_genistein_and_adriamycin_against_estrogen_dependent_and__independent_human_breast_carcinoma_cell_lines_ L2 - https://medlineplus.gov/breastcancer.html DB - PRIME DP - Unbound Medicine ER -